NCT05601726
First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
Phase: Phase 1/2
Role: Lead Sponsor
Start: Nov 8, 2022
Completion: Dec 31, 2026